Company: MDCXW
Filing Date: 2025-09-19
Form Type: DRS
Source: 0001062993-25-015719
Chunk: 227

Company: Medicus Pharma Ltd.
Filing Date: 2025-09-19
Form: DRS
Chunk 227
---
 who are residents of Canada or other countries outside the United States, any judgments in civil and commercial matters, including judgments under the federal securities laws.

<div align='center'>158

CONFIDENTIAL TREATMENT REQUESTED BY MEDICUS PHARMA LTD.

PURSUANT TO 17 C.F.R. SECTION 200.83

WHERE YOU CAN FIND MORE INFORMATION</div>

We have filed with the SEC a registration statement (including amendments and exhibits to the registration statement) on Form S-1 under the Securities Act. This prospectus, which is part of the registration statement, does not contain all of the information set forth in the registration statement. For further information, we refer you to the registration statement and the exhibits and schedules filed as part of the registration statement. If a document has been filed as an exhibit to the registration statement, we refer you to the copy of the document that has been filed. Each statement in this prospectus relating to a document filed as an exhibit is qualified in all respects by the filed exhibit. You should read this prospectus and the documents that we have filed as exhibits to the registration statement of which this prospectus is a part completely. The SEC maintains an internet site at www.sec.gov, from which you can electronically access the registration statement and its exhibits.

<div align='center'>159

INDEX TO FINANCIAL STATEMENTS</div>

| Audited Financial Statements of Medicus Pharma Ltd. for the years ended December 31, 2024 and 2023            | Page |
|:--------------------------------------------------------------------------------------------------------------|:-----|
| Report of Independent Registered Public Accounting Firm (PCAOB ID #274)                                       | F-3  |
| Report of Independent Registered Public Accounting Firm (PCAOB ID #1930)                                      | F-4  |
| Consolidated Financial Statements                                                                             | F-5  |
| Consolidated Balance Sheets                                                                                   | F-6  |
| Consolidated Statements of Operations and Comprehensive Loss                                                  | F-7  |
| Consolidated Statements of Changes in Shareholders' Equity                                                    | F-8  |
| Consolidated Statements of Cash Flows                                                                         | F-9  |
| Interim Financial Statements of Medicus Pharma Ltd. for the three and six months ended June 30, 2025 and 2024 |      |
| Condensed Consolidated Balance Sheets                                                                         | F-25 |
| Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)                            | F-26 |
| Condensed Consolidated Statements of